Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Malignant Mesothelioma Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In the past few years, there has been robust growth in the size of the malignant mesothelioma market. Its size is projected to escalate from $2.46 billion in 2024 to $2.61 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The prior period’s growth can be credited to factors like increased funding in oncology research, a surge in asbestos-related legal cases, growing investments in hospitals, an increase in the aging population, and the expansion of AI-driven drug discovery platforms.
We anticipate vigorous expansion for the malignant mesothelioma market in the coming years. The market is predicted to reach $3.32 billion by 2029, experiencing a compound annual growth rate (CAGR) of 6.3%. This escalation during the forecast period is mainly due to the surge in immunotherapy treatments adoption, heightened emphasis on individualized medication, increased usage of minimally invasive surgical procedures, elevated healthcare expenditure, and an expanding volume of clinical trials. The forecast period is expected to witness key trends such as immunotherapy advancements, personalized medicine progress, initiatives for early detection, minimally invasive surgical innovations, and regulatory approvals.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp
Which Primay Drivers Are Accelerating Growth in the Malignant Mesothelioma Market?
The expansion of the malignant mesothelioma market is projected to be propelled by the escalating efforts in clinical research and development. This involves the execution of scientific trials and studies for the invention of innovative medical devices, treatments, and drugs. Critical aspects of these efforts include assessing the safety, effectiveness, and possible side effects of these new products via controlled clinical trials. The causes for the augmentation in clinical research and development efforts include the rising demand for enhanced and novel treatments, particularly due to the increasing occurrence of complex conditions and chronic diseases. By hastening progress in diagnostics, treatments, and personalised therapies, research and development efforts positively impact the malignant mesothelioma market. They stimulate breakthrough strategies for improving early detection, boosting survival rates, and devising more effective and less intrusive treatment selections. As per a 2025 report by Anadolu Agency, a state-run news agency from Turkey, approximately 40% of the U.S. pharmaceutical research budget, equalling around $7 billion annually, is constituted by clinical trials. Thus, the intensified efforts in research and development are fuelling the expansion of the malignant mesothelioma market.
Which Primary Segments of the Malignant Mesothelioma Market Are Driving Growth and Industry Transformations?
The malignant mesotheliomamarket covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories
Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Malignant Mesothelioma Market?# Market?
North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Malignant Mesothelioma Industry Dynamics?
The foremost firms in the malignant mesothelioma market are prioritizing the creation of cutting-edge treatment alternatives, such as monoclonal antibody therapies, to constrain tumor development and enhance the accuracy of treatment. Monoclonal antibodies are synthesized proteins in the lab that copy the capability of the immune system to identify and aim at distinct antigens like those present on cancer cells. For example, Ono Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, gained additional approval in Japan for the broader application of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody meant for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma) in November 2023. This acknowledgement positions Opdivo as a fresh therapeutic alternative for this disease, where traditional treatments were not formerly identified. Opdivo was granted an orphan drug status for this indication, underlining its potential to meet a substantial medical requirement.
View the full report here:
https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report
What Parameters Are Used to Define the Malignant Mesothelioma Market?
Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22046
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
